Kyowa Kirin Co Ltd

Kyowa Kirin’s new CEO, Abdul Mullick, steers a breakthrough AML therapy and an expanding oncology pipeline, positioning the Tokyo‑listed firm for global growth and investor interest.

Kyowa Kirin Co., Ltd. has strengthened its position in the oncology therapeutics market through strategic partnerships and clinical momentum, including a $30 million development payment and significant overall-survival data from a registry study.

Kyowa Kirin Co., Ltd. has made significant strides in oncology with its promising drug Ziftomenib, receiving FDA priority review and showing positive clinical trial results.